Bridgefront Capital, LLC Acadia Pharmaceuticals Inc Transaction History
Bridgefront Capital, LLC
- $278 Million
- Q4 2024
A detailed history of Bridgefront Capital, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Bridgefront Capital, LLC holds 18,377 shares of ACAD stock, worth $366,621. This represents 0.12% of its overall portfolio holdings.
Number of Shares
18,377
Previous 15,637
17.52%
Holding current value
$366,621
Previous $240,000
40.42%
% of portfolio
0.12%
Previous 0.1%
Shares
4 transactions
Others Institutions Holding ACAD
# of Institutions
316Shares Held
164MCall Options Held
855KPut Options Held
350K-
Baker Bros. Advisors LP New York, NY42.9MShares$855 Million8.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.9MShares$278 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$241 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.71MShares$174 Million2.61% of portfolio
-
Morgan Stanley New York, NY7.3MShares$146 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.23B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...